(Q29616624)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Anticancer activities of histone deacetylase inhibitors (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Jessica E Bolden

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Melissa J Peart

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

29 December 2019

language of work or name

1 reference

30 April 2017

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

29 December 2019

published in

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

5

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

769-784

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

9

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

cites work

The Hallmarks of Cancer

1 reference

Cancer-susceptibility genes. Gatekeepers and caretakers

31 March 2020

1 reference

31 March 2020

Epigenetics and cancer

1 reference

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

31 March 2020

1 reference

Histone modifications: signalling receptors and potential elements of a heritable epigenetic code

31 March 2020

1 reference

Histone acetyltransferases

31 March 2020

1 reference

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

31 March 2020

1 reference

Histone deacetylases and transcriptional therapy with their inhibitors

31 March 2020

1 reference

Histone deacetylase inhibitors in programmed cell death and cancer therapy

31 March 2020

1 reference

Transcriptional regulation in acute promyelocytic leukemia.

31 March 2020

1 reference

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells

31 March 2020

1 reference

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

31 March 2020

1 reference

Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6

31 March 2020

1 reference

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

31 March 2020

1 reference

Expression profile of histone deacetylase 1 in gastric cancer tissues.

31 March 2020

1 reference

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

31 March 2020

1 reference

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

31 March 2020

1 reference

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

31 March 2020

1 reference

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

31 March 2020

1 reference

Increased expression of histone deacetylase 2 is found in human gastric cancer.

31 March 2020

1 reference

HDAC6 expression is correlated with better survival in breast cancer.

31 March 2020

1 reference

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

31 March 2020

1 reference

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

31 March 2020

1 reference

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

31 March 2020

1 reference

Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis

31 March 2020

1 reference

n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells

31 March 2020

1 reference

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

31 March 2020

1 reference

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

31 March 2020

1 reference

Identification of novel isoform-selective inhibitors within class I histone deacetylases

31 March 2020

1 reference

Expression and functional characterization of recombinant human HDAC1 and HDAC3.

31 March 2020

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

31 March 2020

1 reference

Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.

31 March 2020

1 reference

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

31 March 2020

1 reference

Clinical development of histone deacetylase inhibitors as anticancer agents

31 March 2020

1 reference

Prospects: histone deacetylase inhibitors

31 March 2020

1 reference

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

31 March 2020

1 reference

Histone deacetylase inhibitors: from target to clinical trials

31 March 2020

1 reference

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

31 March 2020

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

31 March 2020

1 reference

Life in the balance: how BH3-only proteins induce apoptosis.

31 March 2020

1 reference

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

31 March 2020

1 reference

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

31 March 2020

1 reference

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

31 March 2020

1 reference

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

31 March 2020

1 reference

Reactive oxygen species regulate quiescent T-cell apoptosis via the BH3-only proapoptotic protein BIM

31 March 2020

1 reference

31 March 2020

1 reference

Histone deacetylases and cancer: causes and therapies

31 March 2020

1 reference

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

31 March 2020

1 reference

Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.

31 March 2020

1 reference

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

31 March 2020

1 reference

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

31 March 2020

1 reference

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

31 March 2020

1 reference

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

31 March 2020

1 reference

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

31 March 2020

1 reference

Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells

31 March 2020

1 reference

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

31 March 2020

1 reference

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors

31 March 2020

1 reference

Valproic acid inhibits angiogenesis in vitro and in vivo

31 March 2020

1 reference

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

31 March 2020

1 reference

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

31 March 2020

1 reference

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia

31 March 2020

1 reference

Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials

31 March 2020

1 reference

Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma

31 March 2020

1 reference

Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But

31 March 2020

1 reference

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

31 March 2020

1 reference

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

31 March 2020

1 reference

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

31 March 2020

1 reference

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

31 March 2020

1 reference

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

31 March 2020

1 reference

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

31 March 2020

1 reference

Duration of nuclear NF-kappaB action regulated by reversible acetylation

31 March 2020

1 reference

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

31 March 2020

1 reference

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

31 March 2020

1 reference

Regulation of E2F1 activity by acetylation

31 March 2020

1 reference

Deacetylation of p53 modulates its effect on cell growth and apoptosis

31 March 2020

1 reference

Differential regulation of E2F1 apoptotic target genes in response to DNA damage.

31 March 2020

1 reference

DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes.

31 March 2020

1 reference

HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway.

31 March 2020

1 reference

Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis

31 March 2020

1 reference

Dissecting p53-dependent apoptosis.

31 March 2020

1 reference

WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization.

31 March 2020

1 reference

Regulation of p53 responses by post-translational modifications

31 March 2020

1 reference

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors

31 March 2020

1 reference

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

31 March 2020

1 reference

Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis.

31 March 2020

1 reference

Acetylation of Stat1 modulates NF-kappaB activity

31 March 2020

1 reference

Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells

31 March 2020

1 reference

Acetylation and deacetylation of non-histone proteins

31 March 2020

1 reference

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

31 March 2020

1 reference

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

31 March 2020

1 reference

Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex

31 March 2020

1 reference

Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases

31 March 2020

1 reference

Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes

31 March 2020

1 reference

HSP90 and the chaperoning of cancer

31 March 2020

1 reference

Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

31 March 2020

1 reference

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

31 March 2020

1 reference

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

31 March 2020

1 reference

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

31 March 2020

1 reference

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

31 March 2020

1 reference

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

31 March 2020

1 reference

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

31 March 2020

1 reference

Retinoid therapy of childhood cancer.

31 March 2020

1 reference

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

31 March 2020

1 reference

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

31 March 2020

1 reference

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

31 March 2020

1 reference

Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells

31 March 2020

1 reference

In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

31 March 2020

1 reference

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

31 March 2020

1 reference

New stem cell center at Cornell

31 March 2020

1 reference

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

31 March 2020

1 reference

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

31 March 2020

1 reference

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

31 March 2020

1 reference

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

31 March 2020

1 reference

Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.

31 March 2020

1 reference

Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.

31 March 2020

1 reference

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells

31 March 2020

1 reference

Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol

31 March 2020

1 reference

Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition

31 March 2020

1 reference

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

31 March 2020

1 reference

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

31 March 2020

1 reference

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

31 March 2020

1 reference

Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades

31 March 2020

1 reference

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

31 March 2020

1 reference

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, a

31 March 2020

1 reference

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

31 March 2020

1 reference

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

31 March 2020

1 reference

Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells

31 March 2020

1 reference

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

31 March 2020

1 reference

17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.

31 March 2020

1 reference

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

31 March 2020

1 reference

Aggresomes, inclusion bodies and protein aggregation

31 March 2020

1 reference

Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors

31 March 2020

1 reference

Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor

31 March 2020

1 reference

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

31 March 2020

1 reference

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid

31 March 2020

1 reference

Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death

31 March 2020

1 reference

The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X.

31 March 2020

1 reference

31 March 2020

1 reference

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

31 March 2020

1 reference

Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase

31 March 2020

1 reference

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

31 March 2020

1 reference

Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor

31 March 2020

1 reference

Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy

31 March 2020

1 reference

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

31 March 2020

1 reference

HDAC6 is a microtubule-associated deacetylase

31 March 2020

1 reference

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

31 March 2020

1 reference

Apoptosis: a link between cancer genetics and chemotherapy

31 March 2020

1 reference

The Bcl2 family: regulators of the cellular life-or-death switch

31 March 2020

1 reference

The Bcl-2 family: roles in cell survival and oncogenesis.

31 March 2020

1 reference

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

31 March 2020

1 reference

Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase

31 March 2020

1 reference

FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells

31 March 2020

1 reference

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

31 March 2020

1 reference

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

31 March 2020

1 reference

Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.

31 March 2020

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

31 March 2020

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

31 March 2020

1 reference

Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.

31 March 2020

1 reference

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

31 March 2020

1 reference

Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity

31 March 2020

1 reference

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

31 March 2020

1 reference

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

31 March 2020

1 reference

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

31 March 2020

1 reference

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

31 March 2020

1 reference

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

31 March 2020

1 reference

Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells

31 March 2020

1 reference

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

31 March 2020

1 reference

Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells

31 March 2020

1 reference

A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells

31 March 2020

1 reference

The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53.

31 March 2020

1 reference

The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.

31 March 2020

1 reference

Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells

31 March 2020

1 reference

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

31 March 2020

1 reference

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

31 March 2020

1 reference

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

30 April 2017

Consolidated OpenCitations Corpus – April 2017

28653

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 December 2019

1023003326

0 references

28653

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16955068

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

28653

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955068%20AND%20SRC:MED&resulttype=core&format=json